- Home
- ATON vs BIAF Comparison
ATON vs BIAF Comparison
Compare ATON & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATON | BIAF |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | British Virgin Islands | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ATON | BIAF |
|---|---|---|
| Price | $0.52 | $1.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 143.3K |
| Earning Date | 02-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,776,739.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.69 |
| 52 Week High | $15.82 | $46.53 |
Technical Indicators
Market Signals| Indicator | ATON | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 47.51 |
| Support Level | $0.46 | $0.69 |
| Resistance Level | $0.59 | $1.17 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 9.62 | 64.29 |
Price Performance
Historical ComparisonAbout ATON AlphaTON Capital Corp.
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.